In a report released today, Irina Rivkind Koffler from Mizuho Securities reiterated a Hold rating on Jazz Pharmaceuticals (JAZZ), with a price target of $154. The company’s shares closed yesterday at $141.16.
According to TipRanks.com, Koffler has 0 stars on 0-5 star ranking scale with an average return of -5.8% and a 33.5% success rate. Koffler covers the Healthcare sector, focusing on stocks such as Teva Pharmaceutical Industries Limited, Bausch Health Companies Inc, and Assertio Therapeutics Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Jazz Pharmaceuticals with a $179.57 average price target.
See today’s analyst top recommended stocks >>
Jazz Pharmaceuticals’ market cap is currently $7.99B and has a P/E ratio of 17.60. The company has a Price to Book ratio of 2.94.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Jazz Pharmaceuticals Plc operates as a specialty biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain and psychiatry.
